There is a high incidence of new T2DM at 8% over 4 years among Chinese. Larger BMI, higher glucose levels, and lower levels of ApoA1 are significantly and independently associated with new T2DM. Lower ApoA1 improves the risk prediction of new type 2 diabetes when it was added to the existing risk models.
Aims: Type-2 diabetes mellitus (T2DM) has become a major public health crisis in China. We examined the incidence of new T2DM over 4 years for association of clinical factors and lipids with development of T2DM in a community-based population. Methods:We included 923 Chinese subjects who participated in community-organized health checkout in both 2009 and 2013. Health history was collected; physical examination was performed; biochemistry, lipids and glucose were measured. Of 923, 819 were confirmed without T2DM in 2009 and included in the analysis.Results: Sixty-five subjects without T2DM in 2009 were identified as having new T2DM in 2013, 8% (65/819) over 4 years. These 65 subjects, compared to those 754 without new T2DM, were older, more likely to be male and smokers. They had higher BMI, fasting glucose, blood pressure and triglycerides, and lower levels of HDL-C and ApoA1. Multivariate logistic regression identified larger BMI (OR=1.7, 95%CI 1.22-2.39, p=0.002), higher fasting glucose (OR=4.2, 95%CI 2.90-6.19, p<0.001) and low levels of ApoA1 (OR=0.51, 95%CI 0.33-0.76, p=0.002) were independently associated with development of T2DM over 4 years. ROC curves for new T2DM showed that AUC improved from 0.87 to 0.89 when adding ApoA1 to the Framingham Diabetes Risk Model and from 0.85 to 0.89 when adding ApoA1 to a Chinese model. Conclusions:This study showed a high incidence of new T2DM at 8% over 4 years among Chinese and demonstrated a significant and independent association of higher BMI and glucose levels, and lower levels of ApoA1 with development of T2DM.
To observe the clinical effect of Huatan Quyu granules on type 2 diabetes mellitus combined with nonalcoholic fatty liver disease. A total of 60 patients who met the inclusion criteria were selected from the Department of Endocrinology in the Southern District of Guang'anmen Hospital from January 2018 to December 2019. Thirty patients in the control group were treated with metformin hydrochloride tablets and thirty patients in the treatment group were additionally treated with Huatan Quyu granules after given by metformin hydrochloride tablets. Patients in both groups were treated for 12 w. The blood sugar (fasting plasma glucose, 2 h post-load plasma glucose, hemoglobin A1C), the blood lipids (triglyceride, low-density lipoprotein, high-density lipoprotein, total cholesterol), homeostatic model assessment of insulin resistance and changes in traditional Chinese medicine symptoms of the two groups were compared and analyzed. The total effective rate of traditional Chinese medicine symptoms was better in the treatment group compared with in the control group (p<0.05); the scores of traditional Chinese medicine symptoms, i.e., fullness in the abdomen and stomach, hidden pain under the hypochondrium, dizziness, drowsiness and tastelessness in the mouth, increased in the treatment group after treatment compared with those before treatment and the control group (p<0.05). The fasting plasma glucose, 2 h post-load plasma glucose, hemoglobin A1C, fasting insulin levels, homeostatic model assessment of insulin resistance, triglyceride, total cholesterol, low-density lipoprotein were lower in the treatment group after treatment compared with those before treatment and the control group (p<0.05). Huatan Quyu granules can reduce the biochemical indexes related to glucose and lipids in patients with type 2 diabetes mellitus combined with non-alcoholic fatty liver disease, alleviate insulin resistance and improve the clinical symptoms of patients. It has a good application prospect.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.